Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study by Nakayama, Masaru et al.
RESEARCH ARTICLE Open Access
Carotid artery calcification at the initiation of
hemodialysis is a risk factor for cardiovascular










1 and Yoshiki Kaizu
1
Abstract
Background: Vascular calcification has been recognized as a risk factor for cardiovascular (CV) events in patients
with end-stage renal disease (ESRD). However, the association of carotid artery calcification (CAAC) with CV events
remains unknown. The aim of this study was to elucidate whether CAAC is associated with composite CV events in
ESRD patients.
Methods: One-hundred thirty-three patients who had been started on hemodialysis between 2004 and 2008 were
included in this retrospective cohort study. These patients received multi-detector computed tomography to assess
CAAC at the initiation of hemodialysis. Composite CV events, including ischemic heart disease, heart failure,
cerebrovascular diseases, and CV deaths after the initiation of hemodialysis, were examined in each patient.
Results: CAAC was found in 94 patients (71%). At the end of follow-up, composite CV events were seen in 47
patients: ischemic heart disease in 20, heart failure in 8, cerebrovascular disease in 12, and CV deaths in 7. The
incidence of CAAC was 87% in patients with CV events, which was significantly higher than the rate (62%) in those
without. Kaplan-Meier analysis showed a significant increase in composite CV events in patients with CAAC
compared with those without CAAC (p = 0.001, log-rank test). Univariate analysis using a Cox hazards model
showed that age, smoking, common carotid artery intima-media thickness and CAAC were risk factors for
composite CV events. In multivariate analysis, only CAAC was a significant risk factor for composite CV events
(hazard ratio, 2.85; 95% confidence interval, 1.18-8.00; p = 0.02).
Conclusions: CAAC is an independent risk factor for CV events in ESRD patients. The assessment of CAAC at the
initiation of hemodialysis is useful for predicting the prognosis.
Background
The annual mortality rate due to cardiovascular (CV) dis-
ease in patients with end-stage renal disease (ESRD) is
more than an order of magnitude greater than that in the
population with normal kidney function [1]. Vascular cal-
cification is a common complication of ESRD. Arterial
disease in patients with ESRD is characterized by a high
degree of intimal as well as medial calcification. Arterial
intimal calcification is associated with atherosclerotic
burden, resulting in arterial stenosis or occlusion; on the
other hand, arterial medial calcification is related to
arteriosclerosis, which causes arterial stiffening with
higher systolic blood pressure, increased pulse pressure
and early return of wave reflections, leading to altered
coronary perfusion and left ventricular hypertrophy [2].
It has been demonstrated that vascular calcification is
closely associated with an increased risk of CV events
and mortality in patients with ESRD [3-9]. Therefore, the
fact that CV disease is the leading cause of death in
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of excess vascular calcification.
Most studies that have described the predictive value of
vascular calcification for CV morbidity and mortality have
focused on the following arterial sites: the coronary artery
[5,8], the abdominal aorta [7,9], combined sites such as
the carotid artery, abdominal aorta, iliofemoral axis and
legs [3], the iliofemoral axis [4], and both the pelvis and
hands [6]. On the other hand, several studies have
addressed the association of carotid artery lesions with CV
events and mortality in patients with ESRD. One study
demonstrated that carotid artery plaque was a significant
predictor of CV events [10], and another showed the rela-
tionship between carotid artery stiffening, and all-cause
and CV mortality [11]. In addition, it was demonstrated
that increased intima-media thickness (IMT) of the carotid
artery is a significant predictor of CV deaths [12,13]. In
contrast, in a population-based cohort, the presence of
carotid artery calcification (CAAC), detected by ultrasono-
graphy as calcified plaque, was an independent predictor
of combined vascular events such as stroke, myocardial
infarction or vascular death [14]. However, to date, the
specific impact of CAAC on CV morbidity and mortality
has never been established in chronic kidney disease
(CKD) patients, including patients with ESRD. We have
previously reported the risk factors for CAAC, as evalu-
ated by multi-detector computed tomography (MDCT), in
incident hemodialysis patients by a cross-sectional study
[15]. The aim of the present study was to elucidate
whether the presence of CAAC at the initiation of hemo-
dialysis could be associated with CV events after the initia-
tion of hemodialysis.
Methods
One-hundred thirty-five Japanese patients who were
admitted to our hospital to start maintenance hemodialy-
sis between March 2004 and December 2008 underwent
carotid MDCT examination to assess CAAC. All of the
patients provided written informed consent to the proto-
col, which was approved by the Ethics Committee of
National Kyushu Medical Center Hospital. We previously
reported the risk factors for CAAC and carotid athero-
sclerosis in these 135 patients at the initiation of hemodia-
lysis by a cross-sectional study [15]. After discharge, all
patients underwent maintenance hemodialysis at 40 other
clinics. All of these clinics agreed to record the details of
CV events or death after the initiation of hemodialysis.
Two of 135 patients withdrew informed consent, and the
remaining 133 were enrolled in this retrospective cohort
study. In the present study, CV events were defined as
development of the following conditions after the initia-
tion of hemodialysis: ischemic heart disease, heart failure,
cerebrovascular disease such as brain infarction and
hemorrhage, and CV deaths. CV deaths were defined as
death caused by ischemic heart disease, heart failure,
stroke, sudden death, rupture of an abdominal aortic
aneurysm, ischemic colitis, and peripheral artery disease.
The date of CV events, or date and cause of death were
obtained by reviewing the hospital records. During the fol-
low-up, one patient underwent renal transplantation, and
was censored at that time. When multiple events occurred
in the same patient, only the time to the first event was
analyzed and this first event was defined as an end-point
of composite CV events. The mean follow-up period was
48.5 ± 19.0 (SD) months.
All of the enrolled patients were interviewed and under-
went a clinical examination at the initiation of hemodialy-
sis. Their medical history and outpatient records were also
evaluated in detail. Demographic information (age and
gender), comorbidities (ischemic heart disease, cerebrovas-
cular disease, and peripheral artery disease), and athero-
sclerotic risk factors (hypertension, history of smoking,
dyslipidemia, and diabetes mellitus) at the initiation of
hemodialysis were recorded for each patient. Cigarette
smoking was evaluated as current or past. Dyslipidemia
was defined as plasma triglyceride > 150 mg/dL, plasma
low-density lipoprotein cholesterol > 140 mg/dL, plasma
high-density lipoprotein cholesterol < 40 mg/dL, or use of
lipid-lowering drugs based on a history of dyslipidemia. In
cases in which calcium carbonate, vitamin D3, erythropoi-
esis-stimulating agents (epoetin alfa or beta), statins,
angiotensin-converting enzyme inhibitors, or angiotensin
II receptor blockers had been prescribed, these prescrip-
tions were reviewed before starting hemodialysis. Blood
and urine samples were obtained for serological tests
within a few days before starting maintenance hemodialy-
sis. The systolic and diastolic blood pressures were
recorded as the mean average of pre- and post-dialysis
blood pressures at the last three hemodialysis sessions
during hospitalization at our hospital for the initiation of
hemodialysis (6 measurements). Body mass index (BMI)
was calculated as the dry weight in kilograms divided by
height in meters squared. The criteria for previous CV dis-
ease included a history of ischemic heart disease (docu-
mented myocardial infarction, coronary angioplasty or
bypass surgery, significant coronary artery stenosis con-
firmed by coronary angiography, angina pectoris, or local
asynergy on echocardiography and perfusion defect on
dipyridamole thallium stress scintigraphy), cerebrovascular
disease (documented stroke or transient ischemic attack,
or lacunar infarcts verified by CT or magnetic resonance
imaging), and peripheral artery disease (arteriosclerosis
obliterans).
Carotid CT images were performed to detect calcifica-
tion of common, internal or external carotid arteries,
using a 16-row multidetector CT scanner (Multispeed
Ultra 16x; GE Medical Systems, Milwaukee, WI) with 22.9
mm/s table speed, 512 × 512 pixel matrix, 0.625-mm slice
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energy and autoregulation of tube currents (Figure 1). The
presence or absence of CAAC was assessed by radiologists
who were blinded to the clinical information. High-resolu-
tion B-mode ultrasound was used to assess common caro-
tid artery (CCA)-IMT and carotid artery plaque. The
presence or absence of aortic arch calcification on a plain
chest X-ray was evaluated, and all subjects were assessed
independently by two investigators (S.S. and K.K.) blinded
to the clinical information. The CCA-IMT was taken as
the distance between the lumen-intima interface and the
media-adventitia interface on the B-mode ultrasound
image at 3-cm before the carotid bifurcation. The mean
CCA-IMT was determined for each patient and the aver-
age of both CCA-IMTs was calculated. Carotid artery pla-
que was defined as an area of focal increase in CCA-IMT
(> 1.1 mm) and/or calcified deposits in carotid arteries. A
hyperechoic structure in the walls of common, internal, or
external carotid arteries with an acoustic shadow was
defined as plaque calcification [16]. The ankle-brachial
index (ABI) was also examined in 130 patients (98%).
Those with ABI < 0.9 in either leg were assigned to the
low ABI group [17]. Detailed descriptions of the methods
of ultrasonography and ABI have been reported previously
[15]. The MDCT, ultrasonography and ABI examinations
were performed within 1 week before or after the initiation
of hemodialysis.
Statistical analysis
Continuous data are expressed as either the means ± SD
or median (interquartile range) depending on their distri-
bution, and categorical data are expressed as numbers
(with %). Differences in the pr e v a l e n c ew e r ee v a l u a t e d
using the chi-squared test and Fisher’s exact test for
groups containing less than five individuals in any given
cell. The statistical significance of differences between
groups was examined using the Wilcoxon rank sum test
for nonparametric data or unpaired Student’s t-test for
parametric data. Survival curves were estimated by the
Kaplan-Meier method and evaluated by log-rank test. Risk
factors for outcomes were first examined using a univari-
ate Cox proportional hazards model, and variables with a
significant association (p < 0.10) were then applied to a
multivariate Cox proportional hazards model. Data were
statistically analyzed using the JMP8 statistical package
(SAS Institute, Cary, NC, USA). A P value below 0.05 indi-
cated a statistically significant difference.
Results
Characteristics of the patients
The mean age at the initiation of hemodialysis of the 133
patients (77 men and 56 women) in this study was 64.6 ±
10.5 years (range, 42-88). The primary causes of renal dis-
ease were chronic glomerulonephritis in 23 (17%) patients,
diabetic nephropathy in 59 (44%), hypertensive nephro-
sclerosis in 21 (16%), amyloidosis in 9 (7%), polycystic kid-
ney disease in 5 (4%), other defined causes in 7 (5%) and
unknown in 9 (7%). The primary causes of renal diseases
were diagnosed by renal biopsy in six patients, while the
causes in other patients were determined based on medi-
cal history and clinical findings. Clinical characteristics at
the initiation of hemodialysis of the 133 patients with and
without CAAC are summarized in Table 1. The age of
patients with CAAC was significantly higher than that in
those without. The prevalence of hypertension, dyslipide-
mia and previous CV disease was significantly increased in
patients with CAAC compared with those without. Systo-
lic blood pressure and pulse pressure were higher in
patients with CAAC than in those without. The value of
hemoglobin was significantly lower in patients with CAAC
than in those without CAAC. Calcium-phosphorus pro-
duct in patients with CAAC tended to be higher compared
with that in those without, but no significant difference
was observed. In contrast, the value of C-reactive protein
was significantly higher in patients with CAAC than in
those without. As for carotid artery lesions, both the value
of CCA-IMT and prevalence of carotid artery plaque were
significantly higher in patients with CAAC than in those
without. Half of patients with CAAC showed calcified
plaque confirmed by ultrasonography, while no patients
without CAAC had calcified plaque. MDCT and ultraso-
nography showed an agreement of 64% for the detection
Figure 1 Carotid artery calcification detected by multi-detector
computed tomography at the initiation of hemodialysis was
seen at the origin of the bilateral internal carotid arteries and
left external carotid artery (arrows).
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in 54% of our subjects. The prevalence of aortic arch calci-
fication in patients with CAAC was significantly higher
than in patients without CAAC. In addition, the preva-
lence of low ABI was higher in patients with CAAC than
in those without.
Comparison of clinical findings of the patients with and
without CV events
The number of CV events occurring subsequent to
initiation of hemodialysis was 47. Of the initial CV
events, 20 were ischemic heart disease, 8 were heart fail-
ure, 12 were cerebrovascular disease, and 7 were CV
deaths. Clinical characteristics at the initiation of hemo-
dialysis of 133 patients with and without CV events are
shown in Table 2. There was no difference in demo-
graphics and traditional CV risk factors between the two
groups with and without CV events. The prevalence of
previous CV disease did not differ between the two
groups. With regard to medications which were admi-
nistered after the initiation of hemodialysis, there was
no difference in doses of erythropoiesis-stimulating
agents or the number of patients with angiotensin-con-
verting enzyme inhibitors and/or angiotensin II receptor
blockers between the two groups, while the number of
patients treated with statins was higher in patients with
CV events than in those without CV events. In addition,
the values of non-traditional CV risk factors, e.g., body
mass index, hemoglobin, proteinuria, serum albumin,
calcium-phosphorus product, C-reactive protein and
intact parathyroid hormone did not show a significant
difference between the two groups. Both the value of
CCA-IMT and the prevalence of carotid artery plaque
in patients with CV events tended to be higher com-
pared with those in patients without, but the difference
did not reach significance, and there was no difference
in the prevalence of aortic arch calcification between the
two groups. However, the prevalence of CAAC by
MDCT or calcified plaque by ultrasonography in the
former group was significantly higher than that in the
latter. In addition, among the 87 patients without calci-
fied plaque by ultrasonography, 48 patients had CAAC
by MDCT and 39 patients showed no CAAC. Seventeen
(35%) of the patients with CAAC had CV events and 6
(15%) of the patients without CAAC experienced CV
events; the prevalence of CV events in the former was
significantly higher than that in the latter (p = 0.03).
Risk factors for CV events
The incidence of subsequent CV events in patients with
CAAC was significantly higher than that in patients
without (Log-rank test, p = 0.001), as shown in Figure 2.
Table 3 shows the risk factors for CV events, which
were assessed by a Cox proportional hazards model.
Univariate analysis showed that age, smoking, CCA-
IMT, and CAAC were significant risk factors for CV
events. However, other traditional CV risk factors, such
as hypertension, diabetes and dyslipidemia, were not
identified as risk factors. Additionally, previous CV dis-
ease was not associated with the subsequent CV events.
Non-traditional CV risk factors, e.g., calcium-phos-
phorus product, serum albumin and C-reactive protein,
were also not found to be risk factors. Furthermore, car-
otid artery plaque or aortic arch calcification was not
associated with CV events. In the multivariate analysis,
only CAAC was determined to be an independent risk
factor for CV events.
Table 1 Characteristics of the 133 patients with ESRD
with and without CAAC at the initiation of hemodialysis
Variables CAAC (+) CAAC (-) p value
No. of patients 94 (71) 39 (29)
Age (y) 67.2 ± 10.1 58.3 ± 8.8 < 0.01
Male 57 (61) 20 (51) 0.32
Hypertension 93 (99) 32 (82) < 0.01
Diabetes mellitus 58 (62) 18 (46) 0.10
Dyslipidemia 77 (82) 25 (64) 0.03
Smoking 45 (48) 14 (36) 0.20
Previous CVD 48 (51) 4 (10) < 0.01
Calcium carbonate 26 (28) 13 (33) 0.52
Vitamin D3 14 (15) 5 (13) 0.75
Dose of ESA (U/month) 3000 (0-3000) 1500 (0-3000) 0.47
Statins 26 (28) 5 (13) 0.05
ACEI and/or ARB 50 (53) 20 (51) 0.84
SBP (mm Hg) 158 ± 20 150 ± 23 0.04
DBP (mm Hg) 79 ± 10 82 ± 11 0.13
Pulse pressure (mm Hg) 79 ± 16 68 ± 15 < 0.01
Body mass index (kg/m
2) 20 (18-22) 21 (19-23) 0.04
Blood urea nitrogen (mg/dL) 92 (78-106) 88 (78-120) 0.76
Serum creatinine (mg/dL) 9.0 (7.6-10.2) 9.6 (8.3-11.2) 0.07
Up/Ucr 4.7 (2.3-8.0) 3.7 (1.4-7.3) 0.10
Serum albumin (g/dL) 3.1 ± 0.6 3.4 ± 0.6 0.06
Hemoglobin (g/dL) 8.1 ± 1.1 8.6 ± 1.5 0.02
Ca-P product (mg
2/dL
2) 53.6 (44.2-64.8) 51.9 (42.8-61.4) 0.44
C-reactive protein (mg/dL) 0.15 (0.05-0.44) 0.06 (0.02-0.21) 0.01
intact-PTH (pg/mL) 227 (150-315) 260 (170-420) 0.08
CCA-IMT (mm) 0.83 (0.72-1.10) 0.71 (0.57-0.80) < 0.01
CAP 77 (82) 9 (23) < 0.01
Calcified plaque 46 (49) 0 (0) < 0.01
AAC 67 (71) 5 (13) < 0.01
Low ABI 20 (22) 1 (3) < 0.01
Values are expressed as the mean ± SD, number (%), or median (interquartile
range). Abbreviations: ESRD, end-stage renal disease; CAAC, carotid artery
calcification; CVD, cardiovascular disease; ESA, erythropoiesis-stimulating
agents; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II
receptor blockers; SBP, systolic blood pressure; DBP, diastolic blood pressure;
Up/Ucr, urinary protein-creatinine ratio; Ca-P, calcium-phosphorus; PTH,
parathyroid hormone; CCA-IMT, common carotid artery-intima-media
thickness; CAP carotid artery plaque; AAC, aortic arch calcification; ABI, ankle-
brachial index.
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without all-cause death
At the end of follow-up, 42 total deaths were recorded. The
survival rates at years 3 and 5 were 78% and 66%, respec-
tively. The causes of death were as follows: CV death in 17
patients, malignancy in 9, infection in 6, other defined
causes in 5 and unknown in 5. Table 4 shows the compari-
son of clinical findings at the initiation of hemodialysis of
133 patients according to the presence or absence of all-
cause death. Among the demographics and traditional CV
risk factors, the age in patients with all-cause death was
higher than that in patients without. With regard to medi-
cations which were administered after the initiation of
hemodialysis, no significant difference was observed in
doses of erythropoiesis-stimulating agents or the number
of patients with statins or angiotensin-converting enzyme
inhibitors and/or angiotensin II receptor blockers between
the two groups. Diastolic blood pressure in patients with
all-cause death was significantly lower than that in patients
without. With regard to non-traditional CV risk factors,
the C-reactive protein level was higher in patients with all-
cause death than in those without. As for carotid artery
lesions, both the value of CCA-IMT and prevalence of
CAAC by MDCT or calcified plaque by ultrasonography in
patients with all-cause death were significantly higher than
in those without. The prevalence of aortic arch calcification
in patients with all-cause death was higher than in those
without all-cause death. In addition, the prevalence of low
ABI in patients with all-cause death was significantly higher
than that in patients without.
Risk factors for all-cause mortality
Table 5 shows the results of the Cox proportional
hazards model used to determine the risk factors for
Table 2 Characteristics at the initiation of hemodialysis of the 133 patients with and without cardiovascular events
Variables CV events (+) CV events (-) p value
No. of patients 47 (35) 86 (65)
Age (y) 66.7 ± 9.4 63.4 ± 10.9 0.10
Male 29 (62) 48 (56) 0.51
Hypertension 46 (98) 79 (92) 0.13
Diabetes mellitus 30 (64) 46 (53) 0.25
Dyslipidemia 38 (81) 64 (74) 0.40
Smoking 26 (55) 33 (38) 0.06
Previous CV disease 21 (45) 31 (36) 0.33
Dose of ESA (U/week) 9000 (4500-9000) 9000 (9000-9000) 0.34
Statins 16 (34) 14 (16) 0.02
ACEI and/or ARB 24 (51) 41 (48) 0.71
SBP (mm Hg) 155 ± 15 156 ± 23 0.92
DBP (mm Hg) 78 ± 10 80 ± 10 0.34
Pulse pressure (mm Hg) 76 ± 12 75 ± 19 0.51
Body mass index (kg/m
2) 20 (18-23) 21 (19-22) 0.43
Blood urea nitrogen (mg/dL) 92 (73-114) 90 (80-110) 0.60
Serum creatinine (mg/dL) 8.4 (6.9-9.7) 9.5 (8.3-10.9) < 0.01
Hemoglobin (g/dL) 8.4 ± 1.1 8.1 ± 1.3 0.22
Up/Ucr 4.4 (2.0-7.2) 4.6 (1.8-8.1) 0.75
Serum albumin (g/dL) 3.1 ± 0.6 3.2 ± 0.6 0.43
Ca-P product (mg
2/dL
2) 51.5 (43.7-61.4) 53.3 (43.5-65.0) 0.58
C-reactive protein (mg/dL) 0.14 (0.05-0.44) 0.09 (0.04-0.28) 0.30
intact-PTH (pg/mL) 235 (150-302) 245 (160-381) 0.41
CCA-IMT (mm) 0.83 (0.73-0.97) 0.77 (0.64-0.95) 0.09
CAP 35 (74) 51 (59) 0.08
Calcified plaque 24 (51) 22 (26) < 0.01
CAAC 41 (87) 53 (62) < 0.01
AAC 28 (60) 44 (51) 0.35
Low ABI 10 (22) 11 (13) 0.18
Duration of follow-up (months) 19.2 (9.1-32.5) 51.6 (38.4-65.7) < 0.01
Values are expressed as the mean ± SD, number (%), or median (interquartile range). Abbreviations: CV, cardiovascular; ESA, erythropoiesis-stimulating agents;
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; SBP, systolic blood pressure; DBP, diastolic blood pressure; Up/Ucr, urinary
protein-creatinine ratio; Ca-P, calcium-phosphorus; PTH, parathyroid hormone; CCA-IMT, common carotid artery-intima-media thickness; CAP carotid artery plaque;
CAAC, carotid artery calcification; AAC, aortic arch calcification; ABI, ankle-brachial index.
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variate analysis were as follows: age, serum albumin, C-
reactive protein, CCA-IMT, carotid artery plaque,
CAAC, aortic arch calcification and low ABI. When
these variables were entered into the multivariate analy-
sis, only age was identified as a risk factor for all-cause
mortality; CAAC did not reach the level of statistical
significance.
Discussion
The principal finding of the present cohort study was
that CAAC at the initiation of hemodialysis was con-
firmed to be an independent risk factor for subsequent
CV events in patients with ESRD. Most of the previous
studies assessing vascular calcification in ESRD have
been conducted in patients on maintenance dialysis. In
contrast, to date, only two studies by Block et al. have
been conducted in incident dialysis patients [8,18]. One
of those studies demonstrated that the coronary artery
calcification score at the initiation of hemodialysis is a
significant predictor for all-cause mortality [8]. In the
parent study, subjects without coronary artery calcifica-
tion at the time of hemodialysis initiation did not accrue
substantial calcification during the first 18 months of
dialysis independent of phosphate binder treatment [18].
The current study evaluated CAAC only at the initiation
of hemodialysis, and did not re-examine CAAC after
initiating hemodialysis. Further studies will thus be
needed to elucidate whether or not the progression of
CAAC differs between patients with and without CAAC
at the initiation of hemodialysis.
Most previous studies haveu s e du l t r a s o n o g r a p h yt o
evaluate CAAC as calcified plaque, while in the present
study CAAC was assessed using MDCT. Carotid ultraso-
nography cannot provide a detailed visualization of vas-
cular calcification due to acoustic shadows; however, CT
scans can provide such a visualization [19]. Furthermore,
Figure 2 Kaplan-Meier analysis of the free rate of CV events of
133 patients with end-stage renal disease according to the
presence or absence of CAAC. A comparison between the survival
curves was significant (p = 0.001, Log-rank test). Abbreviations: CV,
cardiovascular; CAAC, carotid artery calcification.
Table 3 Risk factors for cardiovascular events by Cox analysis
Univariate Multivariate
a
Variable HR 95%CI p value HR 95% CI p value
Age 1.03 1.00-1.06 0.04 1.01 0.98-1.05 0.38
Male 1.27 0.71-2.32 0.43 - - -
Hypertension 3.27 0.71-57.9 0.15 - - -
Diabetes Mellitus 1.49 0.83-2.76 0.19 - - -
Dyslipidemia 1.35 0.68-2.97 0.41 - - -
Smoking 1.95 1.09-3.52 0.02 1.73 0.94-3.20 0.08
Previous CV disease 1.40 0.78-2.48 0.26 - - -
Pulse pressure (mm Hg) 1.00 0.99-1.02 0.83 - - -
Body mass index (kg/m
2) 0.98 0.90-1.07 0.69 - - -
Up/Ucr 1.02 0.97-1.07 0.38 - - -
Serum albumin (g/dL) 0.74 0.47-1.17 0.20 - - -
Ca-P product (mg
2/dL
2) 0.98 0.96-1.00 0.11 - - -
C-reactive protein (mg/dL) 1.19 0.66-1.91 0.53 - - -
intact-PTH (pg/mL) 1.00 0.996-1.00 0.14 - - -
CCA-IMT (mm) 2.97 1.20-6.52 0.02 1.51 0.52-3.79 0.43
CAP 1.69 0.90-3.39 0.10 - - -
CAAC 3.78 1.72-9.97 < 0.01 2.85 1.18-8.00 0.02
AAC 1.52 0.85-2.77 0.15
Low ABI 1.77 0.83-3.43 0.13 - - -
Abbreviations: HR, hazard ratio; CI, confidence interval; CV, cardiovascular; Up/Ucr, urinary protein-creatinine ratio; Ca-P, calcium-phosphorus; PTH, parathyroid
hormone; CCA-IMT, common carotid artery-intima-media thickness; CAP, carotid artery plaque; CAAC, carotid artery calcification; AAC, aortic arch calcification; ABI,
ankle-brachial index.
a The multivariate model includes variables for which p < 0.10 by univariate analysis.
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the mineral content of non-moving ex vivo human caro-
tid endarterectomy specimens [20]. Therefore, it is con-
sidered that MDCT is a sensitive method for the
detection of CAAC. However, the method does not allow
differentiation of medial from intimal calcification. It has
been reported that obvious intimal hyperplasia and strik-
ing medial calcification were observed in an analysis of
the morphology of large elastic arteries in ESRD patients
[21], and another study uncovered heavily calcified ather-
osclerotic plaques in patients with ESRD [22]. Consider-
ing these facts, intimal and medial calcification might
coexist in affected vessels in ESRD. In our previous study,
advanced age, hypertension, and disordered calcium-
phosphorus metabolism were shown to be independent
risk factors for CAAC [15], and these risk factors are
considered to be associated with intimal and/or medial
calcification [4,23,24]. Accordingly, CAAC as assessed by
MDCT in the current study is suggested to reflect both
intimal and medial calcification. Furthermore, this sug-
gestion could explain the fact that the prevalence of
CAAC measured by MDCT was twice that of calcified
carotid plaque by ultrasonography in this study, thus sup-
porting the findings of a previous report which demon-
strated ultrasonography to be less accurate than
unenhanced CT in quantifying carotid artery calcium
[25].
On the other hand, as a method for detecting arterial
calcification, simple radiographs are considered inexpen-
sive and involve less radiation exposure than CT. In our
study, aortic arch calcification on a plain X-ray was also
assessed, and the prevalence was 54%, which was similar
to that reported by a previous study [26]. In our study,
the presence of aortic arch calcification was found not to
Table 4 Characteristics at the initiation of hemodialysis of the 133 patients with and without all-cause death
Variables Death (+) Death (-) p value
No. of patients 42 (32) 91 (68)
Age (y) 71.4 ± 8.3 61.4 ± 10.0 < 0.01
Male 27 (64) 50 (55) 0.31
Hypertension 40 (95) 85 (93) 0.67
Diabetes mellitus 23 (55) 53 (58) 0.71
Dyslipidemia 30 (71) 72 (79) 0.34
Smoking 16 (38) 43 (47) 0.32
Previous CV disease 20 (48) 32 (35) 0.17
Dose of ESA (U/week) 9000 (6000-9000) 9000 (6000-9000) 0.92
Satins 10 (24) 20 (22) 0.81
ACEI and/or ARB 16 (38) 49 (54) 0.09
SBP (mm Hg) 153 ± 15 156 ± 23 0.49
DBP (mm Hg) 77 ± 10 81 ± 10 0.03
Pulse pressure (mm Hg) 77 ± 12 75 ± 18 0.55
Body mass index (kg/m
2) 20 (17-23) 21 (19-22) 0.23
Blood urea nitrogen (mg/dL) 89 (73-102) 92 (81-114) 0.09
Serum creatinine (mg/dL) 9.3 (6.9-10.3) 9.2 (8.0-10.7) 0.30
Up/Ucr 4.3 (1.9-7.9) 4.7 (1.9-7.9) 0.66
Serum albumin (g/dL) 3.1 ± 0.5 3.3 ± 0.6 0.11
Hemoglobin (g/dL) 8.3 ± 1.3 8.2 ± 1.3 0.86
Ca-P product (mg
2/dL
2) 51.2 (42.1-57.5) 53.7 (44.2-65.3) 0.18
C-reactive protein (mg/dL) 0.18 (0.07-0.51) 0.07 (0.04-0.25) 0.04
intact-PTH (pg/mL) 235 (168-273) 250 (148-390) 0.32
CCA-IMT (mm) 0.83 (0.74-1.12) 0.76 (0.64-0.90) < 0.01
CAP 32 (76) 54 (59) 0.05
Calcified plaque 23 (55) 23 (25) < 0.01
CAAC 37 (88) 57 (63) < 0.01
AAC 28 (67) 44 (48) < 0.05
Low ABI 12 (29) 9 (10) < 0.01
Duration of follow-up (months) 29.1 (17.8-48.5) 53.6 (45.4-67.8) < 0.01
Values are expressed as the mean ± SD, number (%), or median (interquartile range). Abbreviations: CV, cardiovascular; ESA, erythropoiesis-stimulating agents;
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; SBP, systolic blood pressure; DBP, diastolic blood pressure; Up/Ucr, urinary
protein-creatinine ratio; Ca-P, calcium-phosphorus; PTH, parathyroid hormone; CCA-IMT, common carotid artery intima-media thickness; CAP carotid artery plaque;
CAAC, carotid artery calcification; AAC, aortic arch calcification; ABI, ankle-brachial index.
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Page 7 of 11be a risk factor for CV events; in contrast, CAAC by
MDCT was confirmed to be an independent risk factor
for CV events. Accordingly, although a precise compari-
son of the effectiveness of the two methods would seem
to be difficult due to the different arterial sites (carotid
artery on MDCT vs. aortic arch on X-ray), the evaluation
of CAAC by MDCT might be useful for predicting subse-
quent CV events, which could offset the risk conferred by
the radiation exposure.
It has been reported that calcification in ESRD patients
occurs in the arterial intima in association with athero-
sclerotic plaque [22]. Furthermore, London et al. noted
that intimal calcification was usually observed in older
patients with a clinical history of atherosclerosis and tra-
ditional risk factors for atherosclerotic disease, and that
the odds ratio for the presence of intimal calcification
significantly increases in the presence of carotid artery
plaque [4]. In our previous report, it was also demon-
strated that CAAC was closely associated with carotid
artery plaque, suggesting the association of carotid inti-
mal rather than medial calcification with carotid athero-
sclerosis [15]. Based on these findings, patients with
vascular calcification, including CAAC, appear to have a
greater atherosclerotic burden compared to those with-
out, and this condition might contribute to the poor
prognosis in ESRD patients. In a population-based study,
a positive correlation between calcification in CAAC and
in coronary artery calcification evaluated by multislice
CT was found [27]. It was also reported that the coronary
artery calcium score is associated with an increased risk
of coronary heart disease events in asymptomatic sub-
jects [28]. Based on these findings, CAAC might be asso-
ciated with the occurrence of cardiac events, although
the coronary artery calcification was not assessed in our
study.
Most investigators have postulated that arterial medial
calcification, a common finding in dialysis patients, is
related to vascular stiffness, which in turn results in
adverse CV outcomes. It has been considered that arterial
medial calcification likely increases arterial stiffness and
ventricular afterload [2,29]. Increased arterial stiffness, in
turn, has been associated with increased all-cause or CV
mortality in ESRD patients [11,30,31]. Increased arterial
stiffness could contribute to high pulse pressure [4]. It has
also been reported that higher systolic blood pressure,
lower diastolic blood pressure and wider pulse pressure all
confer greater CV and all-cause mortality risk [32]. How-
ever, in the present study, there was no significant differ-
ence in the values of systolic blood pressure, diastolic
blood pressure, or pulse pressure between the group with
and the group without CV events, or between the group
with and the group without all-cause death. In the Cox
proportional hazards model, these parameters did not
have predictive value for either CV events or all-cause
Table 5 Risk factors for all-cause mortality by Cox analysis
Univariate Multivariate
a
Variable HR 95%CI p value HR 95% CI p value
Age 1.08 1.05-1.12 < 0.01 1.09 1.05-1.14 < 0.01
Male 1.33 0.72-2.56 0.37 - - -
Hypertension 1.33 0.41-8.1
6
0.68 - - -
Diabetes Mellitus 0.92 0.50-1.71 0.79 - - -
Dyslipidemia 0.73 0.38-1.49 0.37 - - -
Smoking 0.81 0.43-1.49 0.50 - - -
Previous CV disease 1.39 0.75-2.55 0.29 - - -
Pulse pressure (mm Hg) 1.00 0.99-1.02 0.65 - - -
Body mass index (kg/m
2) 0.96 0.87-1.05 0.33 - - -
Up/Ucr 1.02 0.97-1.07 0.38 - - -
Serum albumin (g/dL) 0.62 0.38-1.00 0.05 0.89 0.51-1.58 0.67
Ca-P product (mg
2/dL
2) 0.98 0.96-1.00 0.11 - - -
C-reactive protein (mg/dL) 1.64 0.95-2.58 0.07 1.68 0.91-2.92 0.10
intact-PTH (pg/mL) 1.00 0.996-1.00 0.14 - - -
CCA-IMT (mm) 3.76 1.58-8.05 < 0.01 2.20 0.76-6.00 0.14
CAP 1.80 0.92-3.86 0.09 0.59 0.24-1.61 0.29
CAAC 3.87 1.66-11.3 < 0.01 1.83 0.55-6.63 0.33
AAC 1.87 1.00-3.66 < 0.05 0.89 0.43-1.92 0.76
Low ABI 2.70 1.33-5.15 < 0.01 1.83 0.78-3.94 0.16
Abbreviations: HR, hazard ratio; CI, confidence interval; CV, cardiovascular; Up/Ucr, urinary protein-creatinine ratio; Ca-P, calcium-phosphorus; PTH, parathyroid
hormone; CCA-IMT, common carotid artery-intima-media thickness; CAP, carotid artery plaque; CAAC, carotid artery calcification; AAC, aortic arch calcification; ABI,
ankle-brachial index.
a The multivariate model includes variables for which p < 0.10 by univariate analysis.
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Page 8 of 11death. Additionally, the impact of vascular calcification on
CV prognosis according to whether vascular calcification
existed in the intimal or medial layers has not been
directly investigated in previous studies using electron-
beam CT or MDCT. Accordingly, it remains unknown to
what extent medial calcification could have contributed to
the development of CV events or mortality in ESRD
patients in our study.
Unlike in previous reports [10,12,13], carotid artery
plaque or CCA-IMT was not found to be an independent
risk factor for CV events or all-cause death in the current
study. Given that CAAC was an independent risk factor
f o rC Ve v e n t si no u rs t u d y ,t h ea s s e s s m e n to fC A A Ca t
the initiation of hemodialysis could have greater signifi-
cance when predicting the subsequent prognosis. Disor-
dered calcium-phosphorus metabolism is considered to
be one of the modifiable risk factors for vascular calcifi-
cation in CKD [33]. It has been revealed that increased
serum phosphorus and calcium-phosphorus product are
associated with the development of vascular calcification
in uremic patients [23,24], and that higher serum phos-
phorus concentrations that are still within the normal
range are associated with a greater prevalence of vascular
calcification in predialysis patients [34]. In our previous
report, calcium-phosphorus product was a significant
risk factor for the development of CAAC at the initiation
of hemodialysis [15]. In addition, several studies have
identified hyperphosphatemia as an independent risk fac-
tor for CV morbidity and mortality in dialysis patients
[35,36], and it was also demonstrated that in predialysis
patients elevated serum phosphate levels were indepen-
dently associated with increased all-cause mortality [37].
Therefore, the control of disordered calcium-phosphorus
metabolism, especially hyperphosphatemia, is considered
to be one of the key roles for the attenuation of vascular
calcification or prolonged survival in predialysis or dialy-
sis patients; however, few studies have demonstrated the
benefits of reducing serum phosphate concentration on
vascular calcification and mortality. Recent studies have
demonstrated that sevelamer, a non-calcium phosphate
binder, significantly reduces the progression of vascular
calcification in predialysis [38], prevalent [39] and inci-
dent dialysis patients [18]. However, it remains unclear
whether the effect of sevelamer on vascular calcification
is due to phosphate binding without an increase in cal-
cium load or results from the lipid-lowering effect of
sevelamer. Furthermore, given that a significant differ-
ence in all-cause or CV mortality was not found in
patients receiving sevelamer compared with calcium-
based phosphate binders [40,41], it is still unknown
whether this benefit is associated with all-cause or CV
mortality.
The current study has some limitations. Our study
w a sar e t r o s p e c t i v ec o h o r ta n dt h es a m p l es i z ew a s
relatively small. In the present study, CAAC showed a
significant risk factor for all-cause mortality in univari-
ate analysis, but was not identified as a risk factor for
all-cause mortality in multivariate analysis, which was
inconsistent with the previous studies [3-5,7,8]. In the
present study, the proportion of CV deaths to all-cause
deaths was 40%, similar to that reported by Okuno et al.
[7]; conversely, most other studies reported a proportion
of 46% to 64% [3-5]. In addition to the relatively small
sample size, this lower proportion of CV deaths may
have prevented the identification of an independent
association of CAAC with all-cause mortality. Further-
more, the result that only age was an independent risk
factor for all-cause mortality in our study might be attri-
butable to relatively older subjects with a mean age of
64.6 years at the initiation of hemodialysis. MDCT
assessment depended on the presence or absence of
CAAC, but calcium content was not scored. If the
CAAC score were to be quantified, then the relationship
of CAAC scores with CV events could be more precisely
documented.
Conclusions
In conclusion, it was confirmed that CAAC, as detected
by MDCT at the initiation of hemodialysis, was an inde-
pendent risk factor for subsequent CV events. Consider-
ing the result that carotid artery plaque or CCA-IMT,
surrogate markers of subclinical atherosclerosis, did not
have predictive value for CV events, it was suggested
that the assessment of CAAC, among various carotid
artery alterations, was more useful in predicting the
prognosis in ESRD patients.
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